This page describes the editorial standards behind medbot.cn — how content is sourced, verified, reviewed, updated, and corrected. It also discloses the operating entity, reviewer qualifications, and commercial relationships that readers should be aware of when evaluating the information on this site.
Who Reviews Our Content
medbot.cn is operated by Shanghai BIOZENITH Medical Science Co., Ltd. (“Biozenith”), a medical device consulting firm specializing in NMPA registration, clinical trials, and regulatory affairs for international manufacturers entering the Chinese market.
All content is reviewed by the Biozenith regulatory affairs team, which includes professionals with direct experience in Chinese medical device registration pathways, post-market surveillance, and clinical trial protocols. Rather than attributing content to individual authors, we use team-level review because the information synthesized on each page typically draws on multiple regulatory databases, company filings, and trade press — no single reviewer is the sole authority on a given record.
The “Last reviewed” date displayed on each product and company page reflects the most recent team review, not the original publication date. When a page’s underlying data is updated through our monthly refresh process, the review date advances accordingly.
Source Categories and Verification Standards
We classify information into three categories, each with its own verification requirements. See Data Methodology for the full specification.
Regulatory facts — NMPA approval status, CE marking, FDA clearance, registration numbers, and clearance dates. These come only from the issuing authority’s public database, never from company press releases or secondary reporting. Primary sources include the NMPA National Medical Products Administration, EUDAMED, and the FDA 510(k) / PMA databases.
Company-stated facts — Founding year, headquarters, funding rounds, stock codes, leadership, employee counts, and product descriptions. For these, the company itself is the authoritative source of what it publicly states about itself. We record what is published, with the date of the source.
Market claims — Installation counts, market share figures, procedure volumes, and clinical trial headline numbers. These require at least two independent publishing channels before we add them to a record, and the data is displayed alongside the reporting date and source link.
Each source URL is validated at ingest time with a three-step check: the link returns HTTP 200, the target page’s first 500 words mention the company or product by name, and the domain is not on our rejection list of low-quality or AI-generated content farms.
Update Cadence
Data refresh runs monthly. The process includes three tracks:
- Existing record refresh — Each company and product record is re-scanned for updates to company-stated and market-claim fields. Field-category rules determine what can be automatically updated versus flagged for manual review.
- New entrants — NMPA Class II and III approvals in robotics categories over the previous month are cross-checked against our existing catalog. New companies passing a multi-source existence check are added.
- Regulatory status changes — Monitored continuously. Material changes (approvals, revocations, withdrawals) are applied to affected records when verified in the issuing database.
Each monthly refresh produces a git-tagged snapshot, enabling full rollback if a data error is discovered. Weekly internal change summaries support spot-checking.
Corrections Process
We prioritize accuracy, but errors occur. To report a correction, please contact us at the email shown on the About page with:
- The URL of the page containing the error
- The specific field or statement that is incorrect
- The correct information and, where possible, a public source supporting the correction
Regulatory and stated-fact corrections are prioritized and typically acted on within one business week. Narrative or interpretive corrections are reviewed during the next monthly refresh cycle. We do not suppress corrections that would reflect unfavorably on companies documented on the site — accuracy takes precedence over commercial considerations.
Conflict of Interest Disclosure
medbot.cn’s operator, Biozenith, provides paid regulatory and clinical consulting services to medical device manufacturers, including some companies documented on this site. This creates a potential conflict of interest that readers should be aware of.
To mitigate this:
- No editorial preference — Inclusion criteria, ordering, and fact-based coverage are identical for Biozenith clients and non-clients. We do not highlight, prioritize, or omit information based on commercial relationships.
- No paid placements — medbot.cn does not accept payment for inclusion, placement, or removal of content. Biozenith’s commercial CTAs (e.g., “Talk to Biozenith”) are clearly marked and link to the About page or biozenith.net rather than embedded within product or company descriptions.
- Verifiable sourcing — Every data point includes a source link where available, so readers can independently verify the facts on this site.
What This Database Does Not Do
Reading these clarifications is as important as reading what we do cover:
- medbot.cn does not endorse products or recommend purchasing decisions. Regulatory status and specifications are factual records, not recommendations for clinical use or procurement.
- medbot.cn does not provide medical advice. Clinical decisions about the use of any medical robot should be made by qualified healthcare professionals based on current regulatory status and institutional protocols.
- medbot.cn does not publish original clinical efficacy research. Our records reference published trials where relevant, but we do not design, conduct, or peer-review clinical studies.
- medbot.cn does not publish unverified rumors or unattributed claims. Information without a traceable source does not enter the database.
Contact
For editorial inquiries, corrections, or questions about methodology, see the contact details on the About page. For regulatory or clinical consulting inquiries related to Biozenith’s services, visit biozenith.net directly.
Versioning
This editorial policy was last updated on 2026-04-16. Material changes are logged in the site’s git history at github.com/lihengjun/medbot-hugo. For the full data-sourcing specification, see Data Methodology.